Paclitaxel, ifosfamide and cisplatin (TIP) in patients (pts) with poor prognosis nonseminomatous germ cell tumor (NSGCT) with unfavourable serum tumor markers (STM) decline: A phase II study

被引：0
|
作者：
Israelyan, E. R. [1 ]
Tryakin, A. [2 ]
Rumyantsev, A. [1 ]
Fedyanin, M. [3 ]
Tyulyandina, A. [1 ]
Klimov, A. [4 ]
Matveev, V. [5 ]
Volkova, M. I. [6 ]
Paychadze, A. [7 ]
Bychkov, Y. [8 ,9 ]
Yunaev, G. [10 ]
Tsareva, A. [1 ]
Tikhomirova, T. [1 ]
Zorinova, A. [1 ]
Tjulandin, S. [11 ]
机构：
[1] Natl Med Res Ctr Oncol, Chemotherapy Dept 4, Moscow, Russia
[2] Natl Med Res Ctr Oncol, Clin Pharmacol & Chemotherapy Dept, Moscow, Russia
[3] Moscow Dept Hlth, Chemotherapy Dept, Moscow Multidisciplinary Clin Ctr Kommunarka, Moscow, Russia
[4] Natl Med Res Ctr Oncol, Oncourol Dept, Moscow, Russia
[5] NN Blokhin Natl Med Res Ctr Oncol, Oncourol Dept, Moscow, Russia
[6] City Clin Hosp, Moscow Healthcare Dept, Genitourinary Oncol Dept, Oncol Ctr 1, Moscow, Russia
[7] PA Hertsen Moscow Oncol Res Inst, Chemotherapy Dept, Moscow, Russia
[8] Russian Ctr Rentgenoradiol, Chemotherapy Dept, Moscow, Russia
[9] Moscow Res Inst Diagnost & Surg, Chemotherapy Dept, Moscow, Russia
[10] Natl Med Res Ctr Oncol, Intens Care Dept, Moscow, Russia
[11] Natl Med Res Ctr Oncol, Chemotherapy Dept 22, Moscow, Russia
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.770
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
707P
引用
收藏
页码：S543 / S543
页数：1
相关论文
共 50 条
  • [31] Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors:: a phase II study
    Mardiak, J
    Sálek, T
    Sycová-Milá, Z
    Obertová, J
    Hlavatá, Z
    Mego, M
    Recková, M
    Koza, I
    NEOPLASMA, 2005, 52 (06) : 497 - 501
  • [32] SURGICAL RESECTION IN PATIENTS WITH NONSEMINOMATOUS GERM-CELL TUMOR WHO FAIL TO NORMALIZE SERUM TUMOR-MARKERS AFTER CHEMOTHERAPY
    EASTHAM, JA
    WILSON, TG
    RUSSELL, C
    AHLERING, TE
    SKINNER, DG
    UROLOGY, 1994, 43 (01) : 74 - 80
  • [33] Paclitaxel (TAXOL)-ifosfamide-cisplatin (TIP) chemotherapy (CMT) regimen in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study
    Kosmas, C
    Tsavaris, N
    Polyzos, A
    Sepsas, E
    Malamos, N
    Kalofonos, HP
    Panopoulos, C
    Antonopoulos, MJ
    ANNALS OF ONCOLOGY, 1998, 9 : 93 - 93
  • [34] Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).
    Feldman, Darren R.
    Hu, James
    Srinivas, Sandy
    Stadler, Walter Michael
    Costello, Brian Addis
    Appleman, Leonard Joseph
    Milowsky, Matthew I.
    Patil, Sujata
    Bromberg, Maria
    Nolan, Patrick
    Dorff, Tanya B.
    Reuter, Victor E.
    Al-Ahmadie, Hikmat
    Funt, Samuel
    Bajorin, Dean F.
    Bosl, George J.
    Quinn, David I.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors
    Theodore, C.
    Chevreau, C.
    Yataqhene, Y.
    Fizazi, K.
    Delord, J. -P.
    Lotz, J. -P.
    Geoffrois, L.
    Kerbrat, P.
    Bui, V.
    Flechon, A.
    ANNALS OF ONCOLOGY, 2008, 19 (08) : 1465 - 1469
  • [36] Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German testicular cancer study group
    Hartmann, Joerg T.
    Gauler, Thomas
    Metzner, Bernd
    Gerl, Arthur
    Casper, Jochen
    Rick, Oliver
    Horger, Marius
    Schleicher, Jan
    Derigs, Guenter
    Mayer-Steinacker, Regine
    Beyer, Joerg
    Kuczyk, Markus A.
    Bokemeyer, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (36) : 5742 - 5747
  • [37] Efficacy and tolerability of TIP (paclitaxel, ifosfamide and cisplatin) incorporated into induction chemotherapy for patients with intermediate- or poor-risk metastatic germ cell tumors
    Masatomo Nishikawa
    Hideaki Miyake
    Mototsugu Muramaki
    Masato Fujisawa
    Medical Oncology, 2014, 31
  • [38] EFFICACY AND TOLERABILITY OF TIP (PACLITAXEL, IFOSFAMIDE AND CISPLATIN) INCORPORATED INTO INDUCTION CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE- OR POOR-RISK METASTATIC GERM CELL TUMORS
    Nishikawa, Masatomo
    Miyake, Hideaki
    Fujisawa, Masato
    JOURNAL OF UROLOGY, 2015, 193 (04): : E116 - E116
  • [39] Efficacy and tolerability of TIP (paclitaxel, ifosfamide and cisplatin) incorporated into induction chemotherapy for patients with intermediate- or poor-risk metastatic germ cell tumors
    Nishikawa, Masatomo
    Miyake, Hideaki
    Muramaki, Mototsugu
    Fujisawa, Masato
    MEDICAL ONCOLOGY, 2014, 31 (12) : 1 - 7
  • [40] Predictive Value of Modeled AUCAFP-hCG, a Dynamic Kinetic Parameter Characterizing Serum Tumor Marker Decline in Patients With Nonseminomatous Germ Cell Tumor
    You, Benoit
    Fronton, Ludivine
    Boyle, Helen
    Droz, Jean-Pierre
    Girard, Pascal
    Tranchand, Brigitte
    Ribba, Benjamin
    Tod, Michel
    Chabaud, Sylvie
    Coquelin, Henri
    Flechon, Aude
    UROLOGY, 2010, 76 (02) : 423 - U198
12345